Inhibikase raises $4.0M in registered direct offering and warrant inducement

Inhibikase Therapeutics, Inc.

Offering of 1,672,452 shares (or pre-funded warrants) at $1.68/unit with Series A and B warrants.
Warrant inducement: immediate exercise of 708,500 existing warrants at $1.68; repricing of 1,229,484 warrants.
Series A/C warrants exercisable 12 months; Series B/D warrants exercisable 5 years from stockholder approval.
Gross proceeds ~$4.0M; expected closing May 22, 2024; Maxim Group sole placement agent.
Proceeds for general corporate purposes; stockholder approval required for warrant exercisability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.